1: Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019 Nov;134(5):909-917. doi: 10.1097/AOG.0000000000003514. PubMed PMID: 31599847; PubMed Central PMCID: PMC6819023.
2: Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PubMed PMID: 31599840; PubMed Central PMCID: PMC6819021.
3: Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019 Sep;79(14):1599-1606. doi: 10.1007/s40265-019-01187-w. Review. PubMed PMID: 31429064.
4: Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-116. Review. PubMed PMID: 31381550.
5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK544629/ PubMed PMID: 31369224.
6: Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019 Aug;16(8):1226-1235. doi: 10.1016/j.jsxm.2019.05.012. Epub 2019 Jul 2. PubMed PMID: 31277966.
7: Nappi RE, Gardella B. What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions? Expert Opin Pharmacother. 2019 May;20(7):777-779. doi: 10.1080/14656566.2019.1582644. Epub 2019 Feb 26. PubMed PMID: 30806100.
8: Miller MK, Smith JR, Norman JJ, Clayton AH. Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018 Sep;23(3):223-230. doi: 10.1080/14728214.2018.1527901. Epub 2018 Oct 11. Review. PubMed PMID: 30251897.
9: Weinberger JM, Houman J, Caron AT, Patel DN, Baskin AS, Ackerman AL, Eilber KS, Anger JT. Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis. Obstet Gynecol. 2018 Aug;132(2):453-458. doi: 10.1097/AOG.0000000000002733. PubMed PMID: 29995725.
10: Pyke RE, Clayton AH. Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. Sex Med Rev. 2018 Jul;6(3):358-366. doi: 10.1016/j.sxmr.2018.01.003. Epub 2018 Mar 22. Review. PubMed PMID: 29576442.
11: Clayton AH, Kingsberg SA, Goldstein I. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sex Med. 2018 Jun;6(2):59-74. doi: 10.1016/j.esxm.2018.01.004. Epub 2018 Mar 6. Review. PubMed PMID: 29523488; PubMed Central PMCID: PMC5960024.
12: Both S. Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder. Curr Sex Health Rep. 2017;9(4):192-199. doi: 10.1007/s11930-017-0124-3. Epub 2017 Oct 19. Review. PubMed PMID: 29225554; PubMed Central PMCID: PMC5711968.
13: Croft HA. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options. J Sex Med. 2017 Dec;14(12):1575-1584. doi: 10.1016/j.jsxm.2017.10.068. Review. PubMed PMID: 29198512.
14: Petherick A. Sexual arousal: Sex matters. Nature. 2017 Oct 4;550(7674):S2-S3. doi: 10.1038/550S2a. PubMed PMID: 28976951.
15: Gelman F, Atrio J. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017 Jan;8(1):16-25. doi: 10.1177/2040622316679933. Epub 2017 Jan 18. Review. PubMed PMID: 28203348; PubMed Central PMCID: PMC5298357.
16: Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017 Mar;39(3):514-526.e14. doi: 10.1016/j.clinthera.2017.01.018. Epub 2017 Feb 9. PubMed PMID: 28189361.
17: White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017 Apr;35(4):761-768. doi: 10.1097/HJH.0000000000001221. PubMed PMID: 27977473; PubMed Central PMCID: PMC5338879.
18: Seftel AD. Re: Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. J Urol. 2016 Nov;196(5):1516-1517. doi: 10.1016/j.juro.2016.08.063. Epub 2016 Aug 23. PubMed PMID: 27751477.
19: Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16. PubMed PMID: 27181790; PubMed Central PMCID: PMC5384512.
20: Kingsberg SA, Clayton AH, Pfaus JG. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. CNS Drugs. 2015 Nov;29(11):915-33. doi: 10.1007/s40263-015-0288-1. Review. PubMed PMID: 26519340.